0001626199-24-000066.txt : 20240509
0001626199-24-000066.hdr.sgml : 20240509
20240509211307
ACCESSION NUMBER: 0001626199-24-000066
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240507
FILED AS OF DATE: 20240509
DATE AS OF CHANGE: 20240509
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Rickey James Paul
CENTRAL INDEX KEY: 0001606243
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37449
FILM NUMBER: 24932623
MAIL ADDRESS:
STREET 1: ALPINE IMMUNE SCIENCES, INC.
STREET 2: 188 EAST BLAINE STREET, SUITE 200
CITY: SEATTLE
STATE: WA
ZIP: 98102
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: ALPINE IMMUNE SCIENCES, INC.
CENTRAL INDEX KEY: 0001626199
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 208969493
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 188 EAST BLAINE ST., SUITE 200
CITY: SEATTLE
STATE: WA
ZIP: 98102
BUSINESS PHONE: 206-788-4545
MAIL ADDRESS:
STREET 1: 188 EAST BLAINE ST., SUITE 200
CITY: SEATTLE
STATE: WA
ZIP: 98102
FORMER COMPANY:
FORMER CONFORMED NAME: Nivalis Therapeutics, Inc.
DATE OF NAME CHANGE: 20150211
FORMER COMPANY:
FORMER CONFORMED NAME: N30 Pharmaceuticals, Inc.
DATE OF NAME CHANGE: 20141121
4
1
wk-form4_1715303576.xml
FORM 4
X0508
4
2024-05-07
0
0001626199
ALPINE IMMUNE SCIENCES, INC.
ALPN
0001606243
Rickey James Paul
C/O ALPINE IMMUNE SCIENCES, INC.
188 EAST BLAINE STREET, SUITE 200
SEATTLE
WA
98102
0
1
0
0
See Remarks
0
Common Stock
2024-05-07
4
M
0
1
7.55
A
31201
D
Common Stock
2024-05-07
4
M
0
7055
13.20
A
38256
D
Common Stock
2024-05-07
4
M
0
857
6.51
A
39113
D
Common Stock
2024-05-07
4
M
0
164
11.31
A
39277
D
Common Stock
2024-05-07
4
M
0
18286
3.23
A
57563
D
Common Stock
2024-05-07
4
M
0
398
5.02
A
57961
D
Stock Option (Right to buy)
7.55
2024-05-07
4
M
0
1
0
D
2033-01-03
Common Stock
1
108999
D
Stock Option (Right to buy)
13.20
2024-05-07
4
M
0
7055
0
D
2031-01-04
Common Stock
7055
112945
D
Stock Option (Right to buy)
6.51
2024-05-07
4
M
0
857
0
D
2029-02-05
Common Stock
857
143
D
Stock Option (Right to buy)
11.31
2024-05-07
4
M
0
164
0
D
2028-01-01
Common Stock
164
836
D
Stock Option (Right to buy)
3.23
2024-05-07
4
M
0
18286
0
D
2030-01-22
Common Stock
18286
1214
D
Stock Option (Right to buy)
5.02
2024-05-07
4
M
0
398
0
D
2027-04-11
Common Stock
398
137
D
Includes 31,200 shares of common stock underlying a restricted stock unit grant made on January 4, 2024.
The exercise price is equal to the closing price per share of Common Stock as reported on the Nasdaq Global Market on the date of grant.
One-fourth (1/4th) of the Shares subject to the Option will vest on January 4, 2024, and one thirty-sixth (1/36th) of the remaining Shares subject to the Option shall vest each month thereafter, subject to the Reporting Person continuing to be a service provider through each such date.
Twenty-five percent (25%) of the shares subject to the Option shall vest on the one (1) year anniversary of January 5, 2021 (the "Vesting Commencement Date") and one forty-eighth (1/48th) of the shares subject to the Option shall vest each month thereafter on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month), subject to the Reporting Person continuing to be a Service Provider through each such date.
100% of the shares underlying the option were fully vested as of February 6, 2023.
100% of the shares underlying the option were fully vested as of January 2, 2022.
100% of the shares underlying the option were fully vested as of January 23, 2024.
100% of shares underlying the option were fully vested as of April 1, 2021.
Senior Vice President, Chief Financial Officer and Corporate Secretary
/s/ James Paul Rickey
2024-05-09